Long Châu received the Corporate Excellence Award (Asia's Outstanding Enterprise) at the Asia Pacific Enterprise Awards (APEA) 2026, organized by Enterprise Asia, marking its second consecutive year of recognition. The judges cited its efforts in system development, technology innovation, governance, human resources and community activities. The chain has nearly 3,000 pharmacies and more than 240 vaccination centers across 34 provinces and cities, served by more than 22,000 healthcare professionals and more than 36 million loyal customers. The article also describes its use of AI and big data, partnerships with authorities and medical partners, and a long-term health program signed on 13 October with 16 multinational pharmaceutical companies.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Long Châu hai năm liên tiếp là 'Doanh nghiệp xuất sắc Châu Á'
Read the original on VnExpress ↗
Keywords
Long Chauhealthcareartificial intelligenceVietnam
Open a keyword to see other news on the same topic.
Related tickers and likely impact
FRT
▲ Likely positiveFPT Retail
Relevance: low
| Market | Vietnam stocks |
|---|---|
| Exchange | HOSE |
| Sector | Retail |
| Industry | Specialty Retailers |
| Market cap | 25,213 bn VND |
| P/E | 22.2 |
| P/B | 5.25 |
| Close on 10/16/2026 | 141.00 |
| Change that session | 0.00% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Prime Minister: Not Letting People Pay High Prices Due to Intermediary Stages
Prime Minister Lê Minh Hưng said intermediary stages in healthcare, electricity and petroleum distribution will be cut so people do not pay high prices. Under a draft decree on petroleum trading, the number of key petroleum traders is expected to fall to 14-15, with requirements of at least 40 retail stores and storage capacity of at least 15,000 m3. In healthcare, the government will propose amending the Law on Medical Examination and Treatment and the Pharmaceutical Law to cut intermediaries in drug and medical equipment distribution. Inflation was held at 4.52% over nine months, but he said keeping it there will be hard without responsive management, as world fuel prices have risen between 65% and nearly 90%.
- Haleon And 2 British AI Healthcare Stocks To Watch
The article highlights three UK-listed, AI-driven healthcare stocks, while noting that its screen surfaced five more players that are not covered. Haleon sells over-the-counter consumer health brands and uses Microsoft-powered data tools to guide product development and consumer targeting, with revenue of about £3.8b in North America, £2.6b in APAC and £4.7b in EMEA and Latam, and a market value near £33b. Its productivity and AI programme has already delivered 140 basis points of gross margin improvement. Abingdon Health brings AI into diagnostics through its Appdx smartphone reader, earning about £5 million from contract development and £4.1 million from regulatory services, with a market value near £39 million. AstraZeneca generates about $61.4b from pharmaceuticals, has a market value near £193b, and applies AI within its oncology and drug development work. The article also says AI projects that depend heavily on hardware can stall when financing or public support weakens, while software that helps doctors may scale with fewer physical bottlenecks.
- Is UnitedHealth Group Stock a Buy After Another Solid Quarter?
UnitedHealth beat expectations in Q3, with revenue of $112.7 billion (versus $113.2 billion a year earlier and $111.4 billion expected) and adjusted EPS of $4.69 against Wall Street's $4.14 estimate. The company raised its full-year adjusted EPS guidance to at least $20.50, from the previous $19.50 to $20, helped by exiting unprofitable markets and investing in AI. The stock closed just over $401 last week and is up around 22% in 2026, though its five-year returns remain negative. The article says the forward P/E of around 16 is below the more than 19 times that the average S&P 500 stock trades at, and the 2.3% dividend yield adds appeal for income investors. It concludes UnitedHealth remains a worthwhile option given its modest valuation and improving earnings.
- MSB Brings EVERGLOW Experience to M-First Female Customers
MSB held the EVERGLOW event at the M-First Lounge in its Head Office transaction branch to thank female Priority customers in the M-First segment on Vietnamese Women's Day, 20/10. The program featured 1:1 health consultations with the Hong Ngoc Medical System, talks by Phạm Thị Thùy Dương, director of the IVF centre, on health care, and by beauty expert Nguyễn Ngọc Nữ on skincare, along with hands-on activities such as a perfume-making workshop. MSB says the event is part of expanding its M-First privilege ecosystem, linking financial services with quality of life. A related health care program with Hong Ngoc runs from 01/10/2026 to 09/09/2027, offering check-up, screening and VIP benefits, with some benefits extended to members' family members.
- Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It
Warren Buffett, now chairman emeritus of Berkshire Hathaway, warned at the May shareholder meeting that 'we've never had people in a more gambling mood than now,' pointing to individuals rushing into short-term options and market bets. The article argues the S&P 500 and quality stocks have historically recovered from turmoil, and that pharma and biotech firms can hold up in tough times because patients always need treatment. It highlights three picks: Vertex Pharmaceuticals (VRTX), the cystic fibrosis leader that recently purchased Crinetics; Eli Lilly (LLY), whose tirzepatide brought in more than $14 billion of its $23 billion revenue in the recent quarter; and AbbVie (ABBV), where Rinvoq and Skyrizi each grew 24% and which is a Dividend King with more than 50 consecutive years of dividend increases.
- Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Biotech news this week focuses on kidney cancer, multiple sclerosis, Huntington's disease and personalized cancer treatment, as Arcus Biosciences (RCUS), Alnylam (ALNY), Moderna (MRNA) and Merck (MRK) release clinical updates alongside earnings and conferences. Last week, the health care ETF XLV gained 3%, outperforming SPY (down 2%) and QQQ (down 6%), while the biotech ETF XBI fell 6%. Arcus will present kidney-cancer data from its ARC-20 study of Casdatifan, Achieve Life Sciences will report year-long Cytisinicline findings for smoking cessation after a June FDA rejection it says concerned manufacturing and labeling, and Alnylam will share initial Phase 1 ALN-HTT02 results for Huntington's disease. Moderna and Merck will present Phase 3 INTerpath-001 melanoma data on Saturday, comparing individualized treatment intismeran autogene plus Keytruda with Keytruda alone after surgery, while a number of other companies will present multiple sclerosis updates through the week.
Related markets
Latest news
- Earnings live updates: All eyes on Musk and Meta as Q3 earnings rev up
Big tech is the focus of this week's earnings season, with Meta (META), SpaceX (SPCX) and Tesla (TSLA) due to report. SpaceX and Netflix (NFLX) kick off on Tuesday after the bell, while Tesla and Meta report on Wednesday, offering an early read on the Magnificent Seven and the AI trade. Wall Street estimates S&P 500 earnings growth of 29.6%, according to FactSet; if that holds, it would be the third straight quarter of growth above 25%. General Motors (GM), IBM (IBM), United Airlines (UAL) and Procter & Gamble (PG) also report this week.
- Mysterious UAV Enters Lithuania as NATO Fighters Fail to Intercept It
On the morning of October 18, an unidentified drone entered Lithuanian airspace between 6:00 and 8:00, prompting an air alert and the scrambling of NATO jets, which escorted the object but could not shoot it down due to difficult weather. Debris later found in Juojonis village in Pasvalys district was initially identified as drone parts, and the military says it may have entered from Poland. Latvia issued a similar warning for several regions and cancelled it at 8:12, though its army has not confirmed the object was a drone. Prime Minister Mindaugas Sinkevičius said the sabotage hypothesis must be verified, while law enforcement works to determine the drone's origin; earlier, on September 15, Italian Eurofighter Typhoons shot down a drone that had flown into Lithuania from Belarus.
- Corning Is Moving Beyond Fiber Cables. Can AI Networking Pay Off?
Corning (GLW) is extending beyond fiber cables into optical components inside AI systems, having demonstrated optical connectivity with Lumentum and Astera Labs on October 12 and partnered with Nvidia on a planned tenfold expansion of optical connectivity capacity in the US. Its Optical Communications sales rose 32% year-over-year to $2.07 billion in Q2 2026, and management sees a potential $10 billion revenue opportunity by 2030 from a photonics platform, though timing and adoption remain uncertain. Still, the valuation is elevated, with a forward non-GAAP P/E of 44.81x, about 84% above its 5-year average of 24.31x, while analysts expect EPS to grow 30.41% in December 2026 and 33.02% in December 2027. The article notes that slower AI spending or delayed CPO adoption could pressure the stock.
- Google’s Next AI Chip Is Running Late. Why Marvell May Be Fine
GF Securities says one part of Google's TPU v9 design slipped about three weeks, likely due to a redesign, pushing the timeline back roughly a quarter, with mass production now expected in Q2 2027. Packaging substrate yields of just 45% to 50% are a key obstacle, but GF sees no demand problem, citing strong TPU demand from Google and external customers such as Anthropic. The firm points to MediaTek, not Marvell (MRVL), as facing short-term headwinds, so any benefit to Marvell appears indirect. At 63x forward earnings, a 66% premium to its five-year average P/E of 38.02x, the article concludes the delay is not by itself a reason to buy.
- Stocks bounce back, Anthropic's "Public Benefits", and Musk's promise to American kids
The 8:30 show, hosted by Julie Hyman, Pras Subramanian and Jake Conley, discusses the stock market's rebound. Other topics include Anthropic's (ANTH.PVT) commitment to a “Public Benefit” fund, Elon Musk's promise to American children about SpaceX (SPCX) stock ahead of earnings, and doubts over an IPO after Microsoft (MSFT) withdrew.
- Microsoft vs. Alphabet: Is GOOGL’s Cloud Growth Worth More Than Investors Think?
Microsoft (MSFT) and Alphabet (GOOGL) trade at forward P/E ratios of 25.13 and 22.83, respectively. Google Cloud revenue jumped 82% to $24.8 billion in the second quarter, with operating income rising from $2.8 billion to $8.8 billion, while Azure and other cloud services grew 43%. Both companies face heavy infrastructure spending: Microsoft spent $35.8 billion on property and equipment, pushing its cloud gross margin down to 65%, while Alphabet spent $44.9 billion, leaving roughly negative $5.85 billion in quarterly free cash flow. The article argues Alphabet's $9.11 EPS is unreliable because about $98 billion came from net other income, so its 30% operating-income growth better reflects underlying performance. Microsoft has a more diversified earnings base and higher consolidated operating margins, but the key question is whether either company can turn AI demand into cash after paying for infrastructure.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.